Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
ARASAFE
A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients
- NCT05676203 ↗
- Active, not recruiting
- Jena University Hospital
- Standard
We haven't built an HCP commentary report on ARASAFE (docetaxel in metastatic hormone-sensitive prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ARASAFE so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 12 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- A Randomised, Phase 3 Trial Comparing 3-weekly Docetaxel 75 mg/m2 (in a 3 Week Cycle) Versus 2-weekly Docetaxel 50 mg/m2 (in a 4 Week Cycle) in Combination With Darolutamide + ADT in Patients With mHSPC
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Interventions
- Standard ADT (androgen deprivation therapy); Standard Darolutamide; Docetaxel
- Arms
- Arm 1 · Active comparator
- Arm 2 · Experimental
- Enrollment
- 250
- Primary outcomes
- Rate of grade 3-5 AEs
- Sponsor
- Jena University Hospital with Bayer
- Start
- May 16, 2023
- Primary completion
- Jul 3, 2025
- Results posted
- No
- Registry record
- NCT05676203 · updated Aug 5, 2026